Additional Proxy Soliciting Materials (definitive) (defa14a)
06 July 2017 - 12:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
July 5, 2017
Date
of report (Date of earliest event reported)
Nexvet
Biopharma
public limited company
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
|
|
Ireland
|
|
001-36828
|
|
98-1205017
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Number)
|
Unit 5, Sragh Technology Park
Rahan Road, Tullamore
Co. Offaly, R35 FR98, Ireland
(Address of principal executive offices, including zip code)
+353 5793 24522
(Registrants telephone number, including area code)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☒
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or
Rule 12b-2 of
the Securities Exchange Act of 1934 (17
CFR §240.12b-2).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
On July 5, 2017, Nexvet Biopharma public limited company (the
Company
) issued an announcement (the
Rule
2.10 Announcement
) pursuant to Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, that as at the close of business on July 3,
2017 its issued share capital comprised 12,144,941 ordinary shares of $0.125 each.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
|
|
|
Exhibit
|
|
Description
|
|
|
99.1
|
|
Rule 2.10 Announcement, dated July 5, 2017.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
Nexvet Biopharma public limited company
|
|
|
By:
|
|
/s/ Mark Heffernan, Ph.D.
|
Name:
|
|
Mark Heffernan
|
Its:
|
|
Chief Executive Officer
|
Date: July 5, 2017
NEXVET BIOPHARMA PLC (NASDAQ:NVET)
Historical Stock Chart
From Aug 2024 to Sep 2024
NEXVET BIOPHARMA PLC (NASDAQ:NVET)
Historical Stock Chart
From Sep 2023 to Sep 2024